Not everyone's on board with the latest idea in depression

An FDA panel’s endorsement of esketamine, an experimental depression developed by Johnson & Johnson, has been embraced by many mental health experts longing for a new treatment for the condition. Esketamine, the chemical mirror of ketamine, would become the first major depression treatment to hit the market in decades, after all.

But not everyone is so sure that the benefits of the drug outweigh the risks, as STAT’s Megan Thielking reports.

“There’s sort of a split in academia. Some are cheering for something new and others are more skeptical,” said Dr. Erick Turner, a psychiatrist at Oregon Health and Science University who serves on the FDA advisory committee that recently evaluated the drug.

Read more.